Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.62 |
| ▸ | PNP | P00491 | 8/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101894 | 0.99 | PNP (0.61) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL663747 | 0.89 | HPRT1 (0.55) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL27758688 | 0.88 | HPRT1 (0.52) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL27947874 | 0.87 | HPRT1 (0.54) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL16180228 | 0.87 | POLG (0.47) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL443837 | 0.87 | POLG (0.47) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL22434502 | 0.86 | HPRT1 (0.51) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL27780169 | 0.86 | HPRT1 (0.51) | POLGPNPPOLBPOLA1HPRT1 | |
| Ammonia Solution, Strong SCHEMBL27860602 | 0.86 | HPRT1 (0.53) | POLGPNPPOLBPOLA1HPRT1 | |
| SCHEMBL27758695 | 0.86 | PNP (0.53) | POLGPNPPOLBPOLA1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596713-A1 | DNA WITH ENHANCED RESISTANCE AGAINST EXONUCLEASES AND METHODS FOR THE PRODUCTION THEREOF | 4basebio UK Ltd (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2024250923-A1 | CHEMICALLY MODIFIED NUCLEOSIDE, CHEMICALLY MODIFIED NUCLEOSIDE TRIPHOSPHATE AND USE THEREOF | 中国科学院深圳先进技术研究院 | 2024-12-12 | — | — | WO | claimed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | claimed |
| EP-4146285-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| EP-4087611-A1 | SHP2 INHIBITOR DOSING AND METHODS OF TREATING CANCER | Revolution Medicines, Inc. (US) | 2022-11-16 | — | — | EP | claimed |
| CN-115052635-A | Circular RNA compositions and methods | 奥纳治疗公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114929279-A | Methods of administering SHP2 inhibitors and treating cancer | 锐新医药公司 | 2022-08-19 | — | — | CN | claimed |
| EP-3920976-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | claimed |
| WO-2021226597-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | claimed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | claimed |
| US-20100317005-A1 | Modified Nucleotides and Methods for Making and Use Same | Life Technologies Corporation (US) | 2010-12-16 | — | — | US | claimed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | claimed |
| US-20080020994-A1 | G proteins in tumor growth and angiogenesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-20060160723-A1 | biodrug as antilipolytic agents for treating mammal to a weight reduction or reduction in obesity | ASTON UNIVERSITY (GB) | 2006-07-20 | — | — | US | claimed |
| EP-1082344-B1 | GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF | TISDALE MICHAEL JOHN (GB) | 2003-03-19 | — | — | EP | claimed |
| EP-1082344-A2 | GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF | Tisdale, Michael John (GB) | 2001-03-14 | — | — | EP | claimed |
| EP-1032700-A1 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | New York Medical College (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999062939-A2 | GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF | TISDALE MICHAEL JOHN (GB) | 1999-12-09 | — | — | WO | claimed |
| WO-1999006592-A9 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | NEW YORK MEDICAL COLLEGE (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1999006592-A1 | SEPARATION OF NUCLEIC ACIDS BY ANTIBODIES TO HALOGENATED NUCLEOTIDES | NEW YORK MEDICAL COLLEGE (US) | 1999-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NUDT1, RECQL, PNP | POLG 765/4885PNP 3/4885POLB 352/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | POLG 1060/4885PNP 2635/4885POLB 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.